bioAffinity Technologies (BIAF): חובות להיוון בספרים

bioAffinity Technologies (BIAF) occupies a strong niche in oncology diagnostics by developing non-invasive methods for the early detection of lung cancer. This leverage chart, measuring debt to book capitalization, demonstrates financial stability, where the value 0.41 reflects the current magnitude. Stability is bolstered by the absence of geopolitical threats in the US, while the scalability of standardized tests effectively reduces per-study costs.

This ratio determines the proportion of borrowed funds relative to equity, measuring financial stability and default risk. For bioAffinity Technologies (BIAF), the balance sheet debt-to-enterprise capitalization ratio reflects the company's ability to fund diagnostic developments without excessive credit pressure. Low leverage, combined with the legal protections of doing business in the US, minimizes systemic risks. A decrease in this metric guarantees investment security during a recession. However, excessive conservatism may limit expansion rates during periods of market growth.